Hal Barron, Endpoints UKBIO20 (Jeff Rumans)
May 22, 2020 10:14 AM EDTUpdated 10:53 AM
Outsourcing

GSK inks $231M man­u­fac­tur­ing deal as Hal Bar­ron an­tic­i­pates fruit­ful year for pruned R&D group

Amber Tong

Al­most halfway in­to the big turn­around year that Hal Bar­ron has blue­print­ed for Glax­o­SmithK­line’s R&D team, the Big Phar­ma is un­veil­ing a $231 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times